Details for Patent: 11,925,620
✉ Email this page to a colleague
Which drugs does patent 11,925,620 protect, and when does it expire?
Patent 11,925,620 protects OGSIVEO and is included in one NDA.
Drugs Protected by US Patent 11,925,620
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | No | 11,925,620 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Subscribe | ||||
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | RX | Yes | No | 11,925,620 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Subscribe | ||||
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | 11,925,620 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |